Adults with systemic lupus exhibit distinct molecular phenotypes in a cross-sectional study. (March 2020)

• Record Type: Journal Article
• Authors: Guthridge, Joel M.; Lu, Rufei; Tran, Ly Thi-Hai; Arriens, Cristina; Aberle, Teresa; Kamp, Stan; Munroe, Melissa E.; Dominguez, Nicolas; Gross, Timothy; DeJager, Wade; Macwana, Susan R.; Bourn, Rebecka L.; Apel, Stephen; Thanou, Aikaterini; Chen, Hua; Chakravarty, Eliza F.; Merrill, Joan T.; James, Judith A.
• Is Part Of: EClinicalMedicine. Volume 20(2020)
• Publication Date: 2020-03
• Subjects: Systemic lupus erythematosus -- Biomarkers -- Disease activity -- Precision medicine -- Disease subsetting; Medicine -- Research -- Periodicals; Medical policy -- Periodicals; Clinical Medicine; Health Policy; Public Health; Medical policy; Medicine -- Research; Periodical; Electronic journals; Periodicals; 613
• DOI: 10.1016/j.eclinm.2020.100291
• Languages: English
• ISSNs: 2589-5370

Abstract

Abstract: Background: The clinical and pathologic diversity of systemic lupus erythematosus (SLE) hinders diagnosis, management, and treatment development. This study addresses heterogeneity in SLE through comprehensive molecular phenotyping and machine learning clustering. Methods: Adult SLE patients ( n = 198) provided plasma, serum, and RNA. Disease activity was scored by modified SELENA-SLEDAI. Twenty-nine co-expression module scores were calculated from microarray gene-expression data. Plasma soluble mediators ( n = 23) and autoantibodies ( n = 13) were assessed by multiplex bead-based assays and ELISAs. Patient clusters were identified by machine learning combining K-means clustering and random forest analysis of co-expression module scores and soluble mediators. Findings: SLEDAI scores correlated with interferon, plasma cell, and select cell cycle modules, and with circulating IFN-α, IP10, and IL-1α levels. Co-expression modules and soluble mediators differentiated seven clusters of SLE patients with unique molecular phenotypes. Inflammation and interferon modules were elevated in Clusters 1 (moderately) and 4 (strongly), with decreased T cell modules in Cluster 4. Monocyte, neutrophil, plasmablast, B cell, and T cell modules distinguished the remaining clusters. Active clinical features were similar across clusters. Clinical SLEDAI trended highest in Clusters 3 and 4, though Cluster 3 lacked strong interferon and inflammation signatures. Renal activity was more frequent in Cluster 4, and rare in Clusters 2, 5, and 7. Serology findings were lowest in Clusters 2 and 5. Musculoskeletal and mucocutaneous activity were common in all clusters. Interpretation: Molecular profiles distinguish SLE subsets that are not apparent from clinical information. Prospective longitudinal studies of these profiles may help improve prognostic evaluation, clinical trial design, and precision medicine approaches. Funding: US National Institutes of Health